Tumor immunotherapy has shown strong therapeutic potential for stimulating or
reconstructing the immune system to control and kill tumor cells. It is a promising and …

Background: Tumor mutation burden (TMB) have been served as the most prevalent
biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor …

Chemotherapy is an important adjuvant treatment of glioma, while the efficacy is far from
satisfactory, due not only to the biological barriers of blood‒brain barrier (BBB) and blood …

The induction of cytotoxic CD8+ T cell responses requires the presentation of antigenic
peptides by MHC class I molecules (MHC I). MHC I usually present peptides derived from …

Cancer evades host immune surveillance by virtue of poor immunogenicity. Here, we report
an immune suppressor, designated as PTIR1, that acts as a promotor of tumor immune …

Phagocytosis of dying cells constitutes an important mechanism of antigen capture for the
cross-priming of CD8+ T cells. This process has been shown to be critical for achieving …

Major histocompatibility complex class I (MHC I) on antigen presenting cells (APCs) is a
potent molecule to activate CD8+ T cells and initiate immunity. P2X7 receptors (P2X7Rs) are …

In the past decade, rapid advancements in tumor immunotherapy have established it as a
crucial treatment for various kinds of cancers (1). Compared with surgery, radiotherapy and …

This thesis aimed to define the role of reactive oxygen species (ROS), produced by the
NADPH oxidase of myeloid cells, in the regulation of lymphocyte function with focus on ROS …